Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (KS) patients. To date, only one patient with classical KS and treated with standard dose (175 mg/m2) 3-weekly paclitaxel as first line therapy has been reported in the literature. Herein, the first case is presented of a patient with anthracycline-refractory classical KS who was treated with standard dose 3-weekly and paclitaxel after five cycles of therapy achieved a partial response according to the AIDS Clinical Trials Group criteria
Kaposi's sarcoma (KS) is an angioproliferative disease of multifactorial origin arising in different...
Epidemic Kaposi′s sarcoma is one of the malignant neoplasms, which can develop in HIV-infected patie...
Between May 1995 and July 1997, paclitaxel (TX) (175 mg/m2 by 3 h i. v. infusion every 21 days) was ...
Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (K...
Classic Kaposi’s sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males ...
Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there i...
A 77-year-old male patient presented to our attention with violaceous nodular lesions on the skin of...
Copyright © 2013 Zineb Benbrahim et al. This is an open access article distributed under the Creativ...
Paclitaxel (PTX) has been shown to be efficacious with minimal toxicity in patients with AIDS-associ...
PubMedID: 26592833OBJECTIVE: Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clin...
Kaposi's sarcoma (KS) is the most common cancer associated with AIDS. KS aetiology and pathogenesis ...
Kaposi's sarcoma (KS) is the most common malignancy associated with HIV infection and is considered ...
BACKGROUND: Kaposi's sarcoma (KS) is a lymphangioproliferative tumour. Therapy of KS depends on the ...
Paclitaxel is now included in second- and even first-line regimens in advanced breast cancer. The op...
Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeuti...
Kaposi's sarcoma (KS) is an angioproliferative disease of multifactorial origin arising in different...
Epidemic Kaposi′s sarcoma is one of the malignant neoplasms, which can develop in HIV-infected patie...
Between May 1995 and July 1997, paclitaxel (TX) (175 mg/m2 by 3 h i. v. infusion every 21 days) was ...
Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (K...
Classic Kaposi’s sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males ...
Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there i...
A 77-year-old male patient presented to our attention with violaceous nodular lesions on the skin of...
Copyright © 2013 Zineb Benbrahim et al. This is an open access article distributed under the Creativ...
Paclitaxel (PTX) has been shown to be efficacious with minimal toxicity in patients with AIDS-associ...
PubMedID: 26592833OBJECTIVE: Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clin...
Kaposi's sarcoma (KS) is the most common cancer associated with AIDS. KS aetiology and pathogenesis ...
Kaposi's sarcoma (KS) is the most common malignancy associated with HIV infection and is considered ...
BACKGROUND: Kaposi's sarcoma (KS) is a lymphangioproliferative tumour. Therapy of KS depends on the ...
Paclitaxel is now included in second- and even first-line regimens in advanced breast cancer. The op...
Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeuti...
Kaposi's sarcoma (KS) is an angioproliferative disease of multifactorial origin arising in different...
Epidemic Kaposi′s sarcoma is one of the malignant neoplasms, which can develop in HIV-infected patie...
Between May 1995 and July 1997, paclitaxel (TX) (175 mg/m2 by 3 h i. v. infusion every 21 days) was ...